Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $43

Benzinga · 4d ago
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $46 to $43.